

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

In re Entresto (sacubitril/valsartan)  
Patent Litigation

Civil Action No. 20-md-2930-RGA

NOVARTIS PHARMACEUTICALS  
CORPORATION,

Plaintiff,

v.

Civil Action No. 19-2053-RGA

HETERO USA INC., HETERO LABS  
LIMITED, HETERO LABS LIMITED UNIT  
III, MSN PHARMACEUTICALS INC.,  
MSN LABORATORIES PRIVATE  
LIMITED, and MSN LIFE SCIENCES  
PRIVATE LIMITED,

Defendants.

NOVARTIS PHARMACEUTICALS  
CORPORATION,

Plaintiff,

v.

Civil Action No. 22-cv-1395-RGA

MSN PHARMACEUTICALS INC., MSN  
LABORATORIES PRIVATE LIMITED,  
MSN LIFE SCIENCES PRIVATE  
LIMITED, GERBERA THERAPEUTICS,  
INC., and NANJING NORATECH  
PHARMACEUTICAL CO., LIMITED,

Defendants.


**ORDER**

As stated at the August 9, 2024 hearing, Plaintiff Novartis Pharmaceuticals Corporation and Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited are ordered to maintain the status quo until the Court issues its

decisions on the pending motions seeking injunctive relief. (MDL No. 20-2930, D.I. 1422, 1423).

IT IS SO ORDERED.

Entered this 9<sup>th</sup> day of August, 2024

  
United States District Judge